PharmaTher Receives FDA Goal Date of October 29, 2024 for Priority Ketamine ANDA Approval
核心洞察
PharmaTher Holdings received an Amendment Acknowledgment Letter from the FDA with a Generic Drug User Fee Amendments goal date of October 29, 2024 for its Priority Original Abbreviated New Drug Application for ketamine.
The company aims to address the ongoing ketamine shortage in the U.S., as the drug has been on the FDA's drug shortage list since February 2018.
Following anticipated FDA approval, PharmaTher plans to pursue international approvals and develop novel uses and delivery methods of ketamine for pain, mental health, and neurological disorders (搜索).
PharmaTher Holdings Ltd. (搜索) has received an Amendment Acknowledgment Letter from the U.S. Food and Drug Administration setting October 29, 2024 as the Generic Drug User Fee Amendments goal date for its Priority Original Abbreviated New Drug Application for ketamine. The specialty pharmaceutical company announced the milestone following its prompt response to FDA comments regarding possible deficiencies identified during quality review.
Addressing Critical Drug Shortage
The company's ketamine ANDA represents a strategic response to a persistent supply crisis. Ketamine has remained on the FDA's drug shortage list since February 2018, a situation that has encouraged the proliferation of compounded ketamine products not approved by the FDA for psychiatric disorders. The FDA published a compounding risk alert on October 10, 2023, highlighting potential risks associated with these unapproved compounded ketamine products, particularly those provided by telehealth services for in-home administration.
PharmaTher's goal extends beyond addressing the immediate shortage. The company aims to ensure its ketamine product adheres to the FDA's strict manufacturing guidelines and FDA-approved prescribing label, providing a regulated alternative to the current landscape of compounded products.
Regulatory Timeline and Response
The October 29, 2024 goal date follows PharmaTher's receipt of a Complete Response Letter, similar to the review letter the FDA provided regarding possible deficiencies identified by Quality reviewers, as announced on February 12, 2024. Notably, no additional deficiencies were mentioned in the Complete Response Letter and Amendment Acknowledgment Letter.
The company demonstrated its commitment to regulatory compliance by promptly completing necessary tests and responses to address the FDA's comments. This proactive approach resulted in the assignment of the GDUFA goal date, representing a clear pathway toward potential approval.
Clinical Significance and Global Impact
Ketamine holds significant therapeutic importance as an essential medicine listed on the WHO Essential Medicines List for anesthesia and analgesia. In Canada, the drug has been classified as a Tier 3 drug shortage since February 2023, with Health Canada approving ketamine for use as a sedative and painkiller in hospital settings.
Beyond its established indications, ketamine is being administered in hospitals and clinics to treat various mental health, neurological, and pain disorders (搜索). A recently published peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy demonstrated significant patient improvement for depression (搜索), anxiety (搜索), and suicidal ideation (搜索), underscoring the therapeutic potential that PharmaTher seeks to address through regulated channels.
Strategic Vision and Future Development
Following anticipated FDA approval and U.S. market launch, PharmaTher plans to pursue international approvals to support global ketamine demand. The company's long-term strategy encompasses pursuing novel uses and delivery methods of ketamine as a potential treatment for pain, mental health, and neurological disorders (搜索).
This comprehensive approach positions PharmaTher to address both immediate supply needs and future therapeutic innovations in ketamine applications. The company's focus on regulatory compliance and quality manufacturing standards represents a significant step toward resolving the ongoing shortage while ensuring patient safety and therapeutic efficacy.